The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 49-57

  Darpo, B ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

ECG methodology; ICH E14; QT prolongation; Thorough QT QTc study

Indexed keywords

ALFUZOSIN; BRIVARACETAM; DARIFENACIN; DOFETILIDE; ETIRACETAM; IBUTILIDE; LAMOTRIGINE; LEVOCETIRIZINE; MOXIFLOXACIN; NELFINAVIR; RALTEGRAVIR; RITONAVIR; RIVAROXABAN; ROTIGOTINE; SPARFLOXACIN; TOLTERODINE;

CLINICAL EVALUATION; DRUG EFFECT; DRUG INDUSTRY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; HEART RATE; LOW DRUG DOSE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; SENSITIVITY ANALYSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; ELECTROCARDIOGRAPHY; GUIDELINES AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS;

EID: 74549120726     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00487.x     Document Type: Review

References (66)

1. Azie NE, Adams G, Darpo B, Francom SF, Polasek EC, Wisser JM et al. (2004). Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. Ann Noninvasive Electrocardiol 9 : 166 174.
2. Badilini F, Maison-Blanche P (2005). Holter monitoring for QT: the RR bin method in depth. In : Morganroth J Gussak I (eds). Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development. Humana Press, Inc Totowa, NJ, pp. 167 185.
3. Barbey JT, Lazzara R, Zipes DP (2002). Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 7 : 65 76.
4. Bednar MM, Harrigan EP, Ruskin JN (2002). Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 89 : 1316 1319.
5. Benton RE, Sale M, Flockhart DA, Woosley RL (2000). Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 67 : 413 418.
6. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ et al. (2008). The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84 : 475 480.
7. Burke JH, Ehlert FA, Kruse JT, Parker MA, Goldberger JJ, Kadish AH (1997). Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol 79 : 178 181.
8. Couderc JP, Zareba W (2009). An update on QT measurement and interpretation methodologies. Ann Noninvasive Electrocardiol. 14 (Suppl. 1 S1 S2.
9. Couderc JP, McNitt S, Hyrien O, Vaglio M, Xia X, Polonsky S et al. (2008). Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin. Drug Saf 31 : 249 260.
10. Culley CM, Lacy MK, Klutman N, Edwards B (2001). Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 58 : 379 388.
11. Damle B, Fosser C, Ito K, Tran A, Clax P, Uderman H et al 2009). Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study. J Clin Pharmacol 49 : 291 300.
12. Darpo B (2001). Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes. Eur Heart J 3 Suppl. K 70 80.
13. Darpo B (2008). Key issues with TQT studies. Presentation at the DIA meeting '3rd annual cardiac safety conference'. Barcelona December 2008.
14. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P et al. (2006a). Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 46 : 598 612.
15. Darpo B, Nebout T, Sager PT (2006b). Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline. J Clin Pharmacol 46 : 498 507.
16. Demolis JL, Charransol A, Funck-Brentano C, Jaillon P (1996). Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 41 : 499 503.
17. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C (2000). Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 68 : 658 666.
18. Demolis JL, Vacheron F, Cardus S, Funck-Brentano C (2003). Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 73 : 242 252.
19. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K et al 2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 66 : 396 404.
20. Ebert SN, Liu X, Woosley RL (2000). Gender as a risk factor for acquired torsades de pointes. In : Franz MR (ed.). Monophasic Action Potentials: Bridging Cell and Bedside. Futura Publishing Company, Inc Armonk, NY, pp. 659 676.
21. Extramiana F, Maison-Blanche P, Cabanis MJ, Ortemann-Renon C, Beaufils P, Leenhardt A (2005). Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther 77 : 247 258.
22. Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W et al. (2005). Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312 : 1 11.
23. Fossa AA, Wisialowski T, Crimin K (2006). QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization. J Pharmacol Exp Ther 316 : 498 506.
24. Fosser C, Duczynski G, Agin M, Wicker P, Darpo B (2009). Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies. Clin Pharmacol Ther (Epub ahead of print); doi:10.1038/clpt.2009.34.
25. Garnett C (2008). Moxifloxacin needs to be given in a double-blind manner in the TQT study - counterpoint. Presentation at the DIA meeting 'QT and arrhythmia issues in drug development Washington DC April 2008.
26. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N et al. (2008). Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48 : 13 18.
27. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54 : 116 129.
28. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis, A (2007). Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 63 : 1011 1017.
29. Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A (2008). Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 30 : 260 270.
30. ICH E14 Q&A (2008). E14 Implementation working group questions & answers. Available at: http://www.ich.org/LOB/media/MEDIA4719.pdf (accessed 4 June 2008)
31. ICH Harmonized Tripartite Guideline E14 (2005). The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Available at: http://www.ich.org/cache/compo/276-254- 1.html
32. Iwamoto M, Kost JT, Mistry GC, Wenning LA, Breidinger SA, Marbury TC et al. (2008). Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol 48 : 726 733.
33. Kligfield P, Hancock EW, Helfenbein ED, Dawson EJ, Cook MA, Lindauer JM et al. (2006). Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs. Am J Cardiol 98 : 88 92.
34. Kligfield P, Tyl B, Maarek M, Maison-Blanche P (2007). Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes. Ann Noninvasive Electrocardiol 12 : 145 152.
35. Kubitza D, Mueck W, Becka M (2008). Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 31 : 67 77.
36. Leeson PD, Springthorpe B (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6 : 881 890.
37. Li J (2008). PK/PD modelling technique to correct for heart-rate induced QT perturbations. Presentation at the DIA meeting '3rd annual cardiac safety conference'. Barcelona December 2008.
38. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993). Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 : 2590 2597.
39. Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P (2007). Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 81 : 377 385.
40. Malik M (2001). Problems of heart rate correction in the assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12 : 412 420.
41. Malik M (2005). Assessment of drug-induced QT prolongation: to bin or not to bin? Clin Pharmacol The 77 : 241 246.
42. Malik M Andreas JO Hnatkova K Hoeckendorff J Cawello W Middle M et al. (2008). Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 84 : 595 603.
43. Patterson S, Agin M, Anziano R, Burgess T, Chuang-Stein C, Dmitrienko A et al. (2005). Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Report from Pharmaceutical Research and Manufacturer of America QT statistics expert team. Drug Information J 39 : 243 265.
44. Pugsley MK, Authier S, Curtis MJ (2008). Principles of safety pharmacology. Br J Pharmacol 154 : 1382 1399.
45. Rautaharju PM, Zhang ZM (2002). Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J Cardiovasc Electrophysiol 13 : 1211 1218.
46. Rock EP Finkle J Fingert HJ Booth BP Garnett CE Grant S et al. (2009). Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157 : 827 836 I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL (2001). Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285 : 1322 1326.
47. Rosillon D, Astruc B, Hulhoven R, Meeus MA, Troenaru MM, Watanabe S et al 2008). Effect of brivaracetam on cardiac repolarisation - a thorough QT study. Curr Med Res Opin 24 : 2327 2337.
48. Sarapa N (2007). Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG warehouse. Expert Opin Drug Saf 6 : 595 607.
49. Sarapa N, Britto MR (2008). Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf 7 : 305 318.
50. Sarapa N, Morganroth J, Couderc JP, Francom SF, Darpo B, Fleishaker JC et al. (2004). Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. Ann Noninvasive Electrocardiol 9 : 48 57.
51. Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA (2008). Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 83 : 153 159.
52. Sarapa N, Francom SF, Azzam SM, Wickremasingha PK, Tyl B (2009a). Detection of clinically significant QTc prolongation in phase I studies in healthy participants: comparison of 2 semiautomated QT measurement methods. J Clin Pharmacol 49 : 103 108.
53. Sarapa N, Gussak, I, Vajdic B, George S, Hadzievski L, Francom SF et al. (2009b). Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. J Electrocardiol 42 : 358 366.
54. Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A et al 2005). QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 45 : 1038 1047.
55. Shah RR (2002a). Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16 : 147 156.
56. Shah RR (2002b). Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16 : 119 124.
57. Shin JG, Kang WK, Shon JH, Arefayene M, Yoon YR, Kim KA et al. (2007). Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol 63 : 206 215.
58. Strachan IG, Hughes NP, Poonawala MH, Mason JW, Tarassenko L (2009). Automated QT analysis that learns from cardiologist annotations. Ann Noninvasive Electrocardiol 14 (Suppl. 1 S9 21.
59. Strnadova C (2005). The assessment of QT/QTc prolongation in clinical trials: a regulatory perspective. Drug Information J 39 : 407 433.
60. Trepakova ES, Koerner J, Pettit SD, Valentin JP (2009). A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 60 : 45 50.
61. Vik T, Pollard C, Sager P (2008). Early clinical development: evaluation of drug-induced torsades de pointes risk. Pharmacol Ther 119 : 210 214.
62. Wysowski DK, Bacsanyi J (1996). Cisapride and fatal arrhythmia (letter). N Eng J Med 335 : 290 291.
63. Yap YG, Camm AJ (2003). Drug induced QT prolongation and torsades de pointes. Heart 89 : 1363 1372.
64. Zhang J (2008). More lessons learned for TQT studies - FDA perspectives. Presentation at the DIA meeting ′QT and arrhythmia issues in drug development. Washington DC April 2008.
65. Zhang J (2009). Can moxifloxacin be given in a placebo arm during one day of a parallel designed study? Presentation at the DIA meeting '3rd annual cardiac safety conference'. Barcelona December 2008.
66. Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT et al. (2007). QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 49 : 146 153. (Pubitemid 46579948)